MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [8]

Active Indication

BRAF mutated anaplastic thyroid cancerThyroid Cancer with BRAF mutationBRAF V600E mutant Non-small Cell Lung Cancer+ [29]

Inactive Indication

Acute Myeloid LeukemiaAdenocarcinoma of LungAdvanced Bile Duct Carcinoma+ [33]

Originator Organization

Array BioPharma, Inc.

Active Organization

Pfizer Inc.Pierre Fabre Médicament SASPierre Fabre Medicament Information

+ [9]

Inactive Organization

Novartis Pharmaceuticals Corp.

Deciphera Pharmaceuticals, Inc.

Plexxikon, Inc.

Drug Highest PhaseApproved

First Approval Date

US (27 Jun 2018),

BRAF V600 mutation-positive Melanoma

RegulationSpecial Review Project (CN), Orphan Drug (US)

Structure/Sequence

Molecular FormulaC17H15BrF2N4O3

InChIKeyACWZRVQXLIRSDF-UHFFFAOYSA-N

CAS Registry606143-89-9

148

Clinical Trials associated with Binimetinib

NCT05554354

/ RecruitingPhase 2IIT

Phase 2 Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Inactivating or Inferred Inactivating NF1 Alterations: A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares the usual treatment alone (fulvestrant) to using binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer that has spread from where it first started to other places in the body (metastatic) and has an NF1 genetic change. Fulvestrant is a hormonal therapy that binds to estrogen receptors in tumor cells, resulting in estrogen receptor destruction and decreased estrogen binding, which may inhibit the growth of estrogen-sensitive tumor cells. Binimetinib is a targeted therapy that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of binimetinib to fulvestrant in breast cancers with an NF1 genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to fulvestrant alone.

Start Date13 Sep 2024

Sponsor / Collaborator

National Cancer Institute

[+1]

NCT05615818

/ RecruitingPhase 3IIT

Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial

The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.
The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, during which a molecular profile of the patient's tumour will be obtained, and (ii) a randomised comparative trial in which patients with disease control after 4 cycles of standard treatment, and whose tumour harbours a targetable molecular alteration, will be randomised (2:1) to receive either a matched targeted therapy or to continue with the standard treatment.

Start Date18 Jul 2024

Sponsor / Collaborator

UNICANCER

[+8]

NCT06207656

/ RecruitingPhase 2IIT

Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

As a result of the little benefit obtained from standard treatments and the poor prognosis of these patients, the BRAF-V600E mutant MSS aCRC represents an unmet medical need requiring clinical research.
The combination of encorafenib, cetuximab and binimetinib as second- or third-line treatment for mCRC resulted in significantly better outcomes than standard therapy in a phase 3 clinical trial, which also revealed treatment safety and tolerability to be acceptable. Compared to the control group (cetuximab and irinotecan or cetuximab and FOLFIRI), the triplet therapy cohort showed higher median overall survival (9.3 vs. 5.9 months) and response rates (26.8% vs. 1.8%). Grade 3 adverse events occurred in 65.8% and 64.2% of patients for triple-therapy and control groups, respectively.
Based on these results, the investigators speculated that the combination of encorafenib, cetuximab and binimetinib could be used as induction therapy to improve treatment outcomes in BRAF-V600E-mutated MSS aCRC locally advanced initially unresectable but potentially resectable; initially resectable or initially unresectable but potentially resectable oligometastatic disease; and in patients with stage II-IV who have relapsed after chemotherapy (neo and/or adjuvant) or surgery, if the shorter time after resection or from treatment end to relapse is longer than 6 months.

Start Date16 Apr 2024

Sponsor / Collaborator

Merck & Co., Inc.

100 Clinical Results associated with Binimetinib

100 Translational Medicine associated with Binimetinib

100 Patents (Medical) associated with Binimetinib

402

Literatures (Medical) associated with Binimetinib

01 Feb 2025·European Journal of Pharmacology

The efficacy of targeted therapy and/or immunotherapy with or without chemotherapy in patients with colorectal cancer: A network meta-analysis

Review

Author: Guo, Haoyan ; Yu, Chengdong ; Miao, Longjie

BACKGROUNDThe use of targeted drugs and immunotherapy has significantly impacted the treatment of Colorectal Cancer. However, horizontal comparison among various regimens is extremely rare. Therefore, we evaluated the survival efficacy of multiple treatment regimens of targeted therapy and/or immunotherapy with or without chemotherapy in patients with Colorectal Cancer.METHODSA systematic search was conducted in PubMed, EMBASE, and Cochrane databases, covering the period from the establishment of the databases to October 29, 2024. To obtain articles that met the inclusion and exclusion criteria and contained the required data for conducting a network meta-analysis (NMA). The NMA evaluated overall survival (OS) and progression-free survival (PFS).RESULTSA total of 90 studies were identified, comprising a sample size of 33,167 subjects. In terms of PFS, compared with simple chemotherapy strategies, most of the other single or combined strategies are significantly effective, among which targeted therapy strategies have more advantages. Encorafenib + Binimetinib + Cetuximab (ENC-BIN-CET) shows significant benefits in all comparisons except when compared with Chemotherapy + Cetuximab + Dalotuzumab (Chemo-CET-DAL), Encorafenib + Cetuximab (ENC-CET), and Panitumumab + Sotorasib (PAN-SOT). The ENC-CET and PAN-SOT targeted strategies also show significant benefits. Pembrolizumab (PEM) monotherapy has advantages over all others except when it is not superior to some targeted strategies. Chemotherapy + Bevacizumab + Atezolizumab is only inferior to some strategies. In terms of OS, the combinations of Chemotherapy + Bevacizumab, ENC-CET, Chemotherapy + Panitumumab, and ENC-BIN-CET are superior to simple chemotherapy regimens. ENC-BIN-CET shows OS benefits in all comparisons except some. ENC-CET significantly improves OS in most cases, and PEM also significantly improves OS in some regimens. In the probability ranking of OS and PFS, ENC-BIN-CET has the best effect, followed by ENC-CET.CONCLUSIONSIn conclusion, pembrolizumab is still effective in prolonging survival. Dual- and triple-drug targeted strategies are the best in terms of OS and PFS, and the combination of targeted immunotherapy and chemotherapy also works. However, not all combinations are beneficial. As targeted drugs play an active role, specific drugs for colorectal cancer regimens should be carefully selected.

01 Jan 2025·Therapeutic Advances in Medical Oncology

Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF^V600E-mutated metastatic colorectal cancer treated with targeted therapy

Article

Author: Vetere, Guglielmo ; Cremolini, Chiara ; Noto, Laura ; Salvatore, Lisa ; Intini, Rossana ; Sullo, Francesco Giulio ; Taravella, Ada ; Minelli, Alessandro ; Pietrantonio, Filippo ; Salati, Massimiliano ; Scartozzi, Mario ; Calegari, Maria Alessandra ; Ghelardi, Filippo ; Puccini, Alberto ; Antoniotti, Carlotta ; Boccaccio, Chiara ; Lonardi, Sara ; Germani, Marco Maria ; Bensi, Maria ; Lavacchi, Daniele

Background: Encorafenib plus cetuximab (EC) is the standard of care for pre-treated BRAF V600E mutated metastatic colorectal cancer (mCRC). Depth of response (DpR) and early tumour shrinkage (ETS) previously showed a strong correlation with survival outcomes of first-line chemotherapy ± biological agents. Objectives: We aimed to assess potential predictors of primary resistance to EC ± binimetinib (B) and relationships of DpR/ETS with survival outcomes and clinical characteristics. Design: This is a retrospective real-world cohort study of BRAF V600E mutated mCRC patients treated with second-line EC ± B at 20 Italian centres. Methods: Measurable disease according to Response Evaluation Criteria In Solid Tumour (RECIST) 1.1 at baseline and at least one subsequent computed tomography (CT) scan were mandatory for inclusion. Clinical features associated with primary resistance, DpR and ETS were investigated. Relationships of DpR and ETS, both as binary, according to conventional (30% for DpR and 20% for ETS) and median cut-off values, and continuous variables, with progression-free (PFS), overall survival (OS) and duration of response (DoR) were assessed in non-primary resistant patients. Results: A total of 105 patients were included. The primary resistance rate was 28% (29/105) and was associated with baseline peritoneal metastases ( p = 0.04). Disease control and overall response rates were 72% (76/105) and 24% (25/105), respectively, with a median DpR of 15% and an ETS rate of 37% (28/76). Mucinous histology was associated with a significantly lower magnitude of DpR ( p = 0.005) and a lower rate of ETS ( p = 0.002). In the multivariable models, DpR significantly correlated with longer PFS as a dichotomous variable, according both to conventional (hazard ratio (HR)DpR ⩾30%: 0.52, 95% CI: 0.30–0.90, p = 0.02) and median cut-off values (HRDpR⩾15%: 0.55, 95% CI: 0.33–0.92, p = 0.03), and as a continuous variable (HR per 10% increment: 0.88, 95% CI: 0.78–0.98, p = 0.02), while correlations with OS were not confirmed. DpR was also significantly associated with longer DoR ( pDpR⩾30% = 0.04; pDpR⩾15% = 0.04; pcont. = 0.02), whereas no relationships of ETS with PFS, OS or DoR were detected. Conclusion: A DpR of at least 15% independently predicts PFS benefit in BRAF V600E mutated mCRC patients treated with second-line EC ± B.

31 Dec 2024·CNS Oncology

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab

Article

Author: Kato, Ken ; Shoji, Hirokazu ; Takashima, Atsuo ; Hirano, Hidekazu ; Okita, Natsuko ; Awatsu, Takahito ; Matsuguma, Kunihito ; Hirose, Toshiharu ; Imai, Toru

This report describes a case of BRAF V600E-mutated colorectal cancer with CNS metastases in which treatment with encorafenib, binimetinib and cetuximab was effective. There is limited information on the ability of encorafenib, binimetinib and cetuximab to enter the CNS.The patient was a 53-year-old man was diagnosed with ascending colon cancer (cT3N3M1c stage IVc). BRAF V600E mutation was confirmed. FOLFOX was started, but CNS metastases soon appeared. Encorafenib, binimetinib and cetuximab were administered and had a favorable effect on the CNS lesions. The patient initially responded well, but his disease progressed 2 months later. Further research is needed to improve management strategies for BRAF V600E-mutated colorectal cancer with CNS metastases.

News (Medical) associated with Binimetinib

09 Jan 2025

·www.businesswire.com

FORE Biotherapeutics Highlights Recent Pipeline Achievements for its Targeted-Oncology Program and Provides Strategic Objectives for 2025

PHILADELPHIA--( BUSINESS WIRE )--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today highlighted its recent pipeline achievements and provided its key strategic objectives for 2025. William Hinshaw, Chief Executive Officer of Fore Biotherapeutics, will detail progress and discuss anticipated milestones in a presentation at the 43 rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 14, 2025, at 5:30 p.m. PT in San Francisco, CA. “ 2025 will be an exciting year at Fore, with multiple value-creating catalysts anticipated in the near-term across our trials. Our focus in 2025 will be continued execution of our differentiated monotherapy development of plixorafenib, which represents a multi-billion dollar opportunity, and the potential for expansion into developing plixorafenib as a combination agent. Plixorafenib’s unique mechanism of action supports the potential to reset the standard for patients with BRAF driven tumors, which have been underserved and underpenetrated due to the limitations of current agents. Plixorafenib is designed to inhibit not only the constitutively active BRAFV600 monomers targeted by first-generation RAF inhibitors, but also disrupt constitutively active dimeric BRAF class II mutants, fusions, splice variants and others, which differentiates it from current approved therapies. We are encouraged by the compelling safety and efficacy profile we have seen and the progress in our registrational trials,” said William Hinshaw, Chief Executive Officer of Fore. 2024 Achievements Strengthened Leadership Team: In 2024, Fore strengthened its leadership team with the appointment of William Hinshaw as Chief Executive Officer, Michael Byrnes as Chief Financial Officer and Payman Darouian, as Senior Vice President, Corporate Development, Strategy and Commercial. The new management team brings extensive experience from large pharmaceutical companies and multiple high-growth, publicly traded biotechnology companies adding to the strong existing capabilities of the team. Continued Execution of FORTE Master Protocol: The FORTE Master Protocol is a global clinical trial which includes baskets evaluating plixorafenib in distinct patient populations. The three monotherapy indications currently under evaluation are BRAF V600 Recurrent Primary Central Nervous System (CNS) Tumors, Rare BRAF V600 Mutated Solid Tumors and Solid Tumors with BRAF Fusions. Advanced Plixorafenib in BRAF V600 Recurrent Primary Central Nervous System Tumors: Continued enrollment in registration-intended basket in up to 50 patients with BRAF V600-mutated recurrent primary CNS tumors. This BOP2 design trial enrolls patients who are naïve to MAPK pathway inhibitor (MAPKi) treatment. Major efficacy endpoints include overall response rate (ORR) and duration of response (DOR). The study builds upon a previous clinical trial of plixorafenib in which six out of nine, or 67%, of MAPKi naïve adults with recurrent BRAF V600-mutated primary CNS tumors demonstrated a partial response (PR) with a median DOR (mDOR) of 13.9 months. Advanced Plixorafenib in Rare BRAF V600 Mutated Solid Tumors: Initiated enrollment in registration-intended basket in up to 75 patients with rare BRAF V600-mutated solid tumors. This BOP2 design trial enrolls patients who are naïve to MAPKi treatment. Major efficacy endpoints include ORR and DOR. The study builds upon a previous clinical trial of plixorafenib in which 42% of MAPKi naïve adults with BRAF V600-mutated solid tumors demonstrated a PR with a mDOR of 17.8 months. Advanced Plixorafenib in Solid Tumors with BRAF Fusions: Continued enrollment in registration-intended basket in up to 75 patients with BRAF fusion advanced solid tumors. This BOP2 design trial enrolls patients with tumors harboring BRAF fusions, excluding those with prior treatment with MAPK inhibitors as well as patients with colorectal or pancreatic ductal adenocarcinoma. The primary endpoint is ORR, as determined by RANO criteria or RECIST v1.1 for primary CNS tumors or other solid tumors, respectively. The study builds upon a previous clinical trial of plixorafenib that demonstrated promising single agent activity including one complete response with a DOR of 66.7+ months, one PR with a DOR of 9.2+ months, and seven stable disease, out of 14 adults evaluable for efficacy. Reported Supportive Nonclinical Data at AACR 2024: Fore reported nonclinical data at AACR 2024 demonstrating that plixorafenib in combination with binimetinib, a MEK inhibitor, is more potent than other BRAF and pan-RAF inhibitors combined with binimetinib, as well as the synergistic activity of plixorafenib with MEK inhibition across all BRAF alterations tested. Reported Supportive Safety and Efficacy Data at International Symposium on Pediatric Neuro-Oncology (ISPNO 2024): Fore reported safety and efficacy data at ISPNO 2024 building on the existing evidence of plixorafenib in children and adults with BRAF-altered recurrent primary CNS tumors. Reported Supportive Safety and Efficacy Data in Ovarian Cancer at 15 th Biennial Ovarian Cancer Research Symposium (OCRS): Fore reported safety and efficacy data at OCRS 2024, including durable partial responses in three out of three patients with BRAF V600-mutated ovarian cancer, who were all heavily pre-treated. 2025 Strategic Objectives and Anticipated Milestones Continued Execution of the FORTE Master Protocol with Interim Analyses in Three Monotherapy Indications Anticipated in 2025 BRAF V600 Primary Recurrent Central Nervous System Tumors: An interim efficacy analysis from the first 25 evaluable patients is anticipated to be conducted in the third quarter of 2025. Pending a positive recommendation from the data monitoring committee, topline data from this trial would be anticipated in the second half of 2026. The company anticipates that this trial, with sufficient demonstration of safety and efficacy, would enable the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under the Accelerated Approval pathway. Rare BRAF V600 Mutated Solid Tumors: An interim efficacy analysis from the first 25 evaluable patients is anticipated to be conducted in the fourth quarter of 2025. Advanced Solid Tumors with BRAF Fusions: An interim efficacy analysis from the first 25 evaluable patients is anticipated to be conducted in the fourth quarter of 2025. About FORE Biotherapeutics Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1 st and 2 nd generation BRAF inhibitors. Plixorafenib has demonstrated single-agent efficacy signals across a variety of tumor types with a manageable safety profile in a Phase 1/2a clinical trial of over 100 patients and is currently enrolling patients in FORTE, a global registrational basket trial to support three distinct indications. For more information, please visit www.fore.bio or follow us on X and LinkedIn .

Clinical ResultExecutive Change

07 Jan 2025

·endpts.com

Immuneering touts positive pancreatic cancer data for MEK inhibitor

Immuneering’s shares rocketed in premarket trading on Tuesday on the back of positive mid-stage data for its MEK inhibitor in pancreatic cancer, sparking plans to add more combination arms. Three out of seven patients with first-line pancreatic cancer given the biotech’s IMM-1-104 plus modified gemcitabine/nab-paclitaxel reached a complete or partial response in the Phase 2a study, according to a release . The numbers translate to a 43% overall response rate. For context, gemcitabine/nab-paclitaxel are linked to a 23% ORR in this setting, according to the company. Immuneering’s shares $IMRX were up 44% at market open Tuesday, though the stock was trading up at about 5% by mid-morning. Several MEK inhibitors are already on the market for melanoma including Pfizer’s Mektovi and Novartis’ Mekinist. But these treatments are mainly approved to treat patients with BRAF-driven tumors. Immuneering said IMM-1-104 is designed to be effective in a broader range of cancers — including RAS-mutated tumors — and could offer better safety. In a separate cohort of Phase 2 patients with first-line pancreatic cancer, all four evaluable subjects treated with IMM-1-104 plus modified FOLFIRINOX saw tumor shrinkage and disease control. Elsewhere, eleven out of 21 second-line pancreatic cancer patients given IMM-1-104 as a single agent achieved disease control. The company said the drug was “very well tolerated” in this cohort, with all side effects grade 1 or 2 in severity. Following the positive results, Immuneering plans to add more cohorts to the trial — one will test IMM-1-104 with a BRAF inhibitor in certain patients with melanoma, and two others will evaluate the drug plus checkpoint inhibitors in melanoma and non-small cell lung cancer. Back in September, the drugmaker reported initial promising results from five pancreatic cancer patients. At the time, Chardan analysts cautioned the data “came from a very small number of patients.”

Clinical ResultPhase 2Phase 1

23 Dec 2024

·www.pharmaceutical-technology.com

Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA

Pfizer holds exclusive rights to BRAFTOVI in the Middle East, Canada, Latin America, Africa, and the US. Credit: ShU studio/Shutterstock. Pfizer has gained accelerated approval from the US Food and Drug Administration (FDA) for BRAFTOVI (encorafenib) in conjunction with cetuximab and mFOLFOX6 for treating metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, confirmed by an FDA-approved test. This decision follows a significant improvement in response rate and durability response observed in the treatment-naïve subjects in the randomised, open-label, multicentre Phase III BREAKWATER trial that demonstrated an overall response rate of 61% with the BRAFTOVI regimen compared to 40% in the control arm. The ongoing active-controlled trial assesses the combination with or without mFOLFOX6 chemotherapy in previously untreated mCRC subjects with the BRAF V600E mutation. FDA has granted this accelerated approval with the condition that further clinical benefits be verified for continued approval. This accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development. Pfizer executive vice-president and chief oncology officer Chris Boshoff said: “For more than a decade, Pfizer has been a pioneer in delivering targeted therapies for molecular-driven cancers. With today’s accelerated approval of the BRAFTOVI regimen, patients with metastatic colorectal cancer with a BRAF V600E mutation now have a first-line treatment option, which contains a targeted therapy specifically for a mutation that is driving their cancer. “This milestone adds to our legacy of developing innovative medicines in BRAF tumours, some of the hardest-to-treat cancers. We look forward to continuing to expand our portfolio, including the exploration of a next-generation brain-penetrant BRAF inhibitor.” Pfizer’s application for BRAFTOVI received priority review and utilised the Real-Time Oncology Review (RTOR) pilot programme. Reviews are currently ongoing in Brazil and Canada, with discussions with other regulatory authorities globally to support additional licensing applications for the BRAFTOVI combination regimen. In October 2023, the US regulator approved the combination of BRAFTOVI and Mektovi for treating metastatic non-small cell lung cancer (NSCLC). Pfizer holds exclusive rights to BRAFTOVI in Canada, Latin America, the Middle East, Africa, and the US while Ono Pharmaceutical , Medison, and Pierre Fabre have rights in other specific territories.

Phase 3Priority ReviewAccelerated ApprovalLicense out/inDrug Approval

100 Deals associated with Binimetinib

External Link

KEGG	Wiki	ATC	Drug Bank
D10604	Binimetinib	L01XE41	DB11967

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
BRAF mutated anaplastic thyroid cancer	JP	Ono Pharmaceutical Co., Ltd.	17 May 2024
Thyroid Cancer with BRAF mutation	JP	Ono Pharmaceutical Co., Ltd.	17 May 2024
BRAF V600E mutant Non-small Cell Lung Cancer	US	Array BioPharma, Inc.	11 Oct 2023
BRAF mutation positive Melanoma	JP	Ono Pharmaceutical Co., Ltd.	08 Jan 2019
Melanoma	AU	Pierre Fabre SA	03 Jan 2019
BRAF V600 mutation-positive Melanoma	CA	Pfizer Canada ULC	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	Preclinical	AU	Pfizer Inc.	27 Jun 2013
Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	Preclinical	AT	Pfizer Inc.	27 Jun 2013
Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	Preclinical	PL	Pfizer Inc.	27 Jun 2013
Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	Preclinical	HU	Pfizer Inc.	27 Jun 2013
Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	Preclinical	IT	Pfizer Inc.	27 Jun 2013
Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	Preclinical	DK	Pfizer Inc.	27 Jun 2013
Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	Preclinical	ES	Pfizer Inc.	27 Jun 2013
Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	Preclinical	CA	Pfizer Inc.	27 Jun 2013
Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	Preclinical	IE	Pfizer Inc.	27 Jun 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03843775 (CTgov)	Phase 1/2	BRAF mutation Solid Tumors	17	Encorafenib+Binimetinib (Dose Level 1)	(vfwfbpjopk) = wqeafpagcs mixnlboazq (ywpeqetofj, dbnzvbanqe - eduuqcxuil) View more	-	21 Oct 2024
				Encorafenib+Binimetinib (Dose Level 2)	(evpmnulyby) = mejbfcwinn hbzdliymjb (otkkofzjrz, lzrvypcjur - wgmrujnzsf) View more
NCT03864042 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm \| Metastatic melanoma \| Unresectable Melanoma \| BRAF V600 mutation-positive Melanoma	56	omeprazole+encorafenib+midazolam+caffeine+binimetinib+dextromethorphan+losartan (Arm 1 - CYP Probe Cocktail)	stagrqnjni(fiyhbgztls) = mnrtymhbfv kzshjdtkql (juwcgevbgv, ufocgjhjhe - eylcytscpu) View more	-	27 Sep 2024
				rosuvastatin+bupropion immediate release (IR)+encorafenib+binimetinib (Arm 2 - Rosuvastatin and Bupropion)	asheshjbny(afjvjhjcet) = jkmmnzouis lfpebxosga (fsyopjujva, hkrjhtdmtl - kvzqucnzcm) View more
NCT04526782 (IFCT-1904 \| ENCO-BRAF, ESMO2024) Manual	Phase 2	BRAF V600E mutant Non-small Cell Lung Cancer First line BRAF V600E-mutant	64	encorafenib 450mgbinimetinib	(djwvwbrhpg) = qcqijeboiv gwnbyyzauj (yxrpqbsefj, 55.0 - 78.3) View more	Positive	14 Sep 2024
NCT04913285 (KN-8701, ESMO2024) Manual	Phase 1	NRAS Mutant Melanoma \| BRAF mutation Solid Tumors	52	Exarafenibbinimetinib	(pmjcuuvemb) = blurred vision (n=1), CPK increased (n=1), GI bleed, nausea, neuralgia, & renal injury (n=1) cgacjodkir (mqppqbfykr ) View more	Positive	14 Sep 2024
NCT03915951 (PHAROS, WCLC2024) Manual	Phase 2	BRAF V600E mutant Non-small Cell Lung Cancer Second line \| First line	98	Encorafenib 450 mBinimetiniby plus Binimetinib 45 mg twice daily	(rtqknqqhzz) = gluyffricn lvmlvtnyeq (orodxnfyyv ) View more	Positive	10 Sep 2024
				EncorafenibBinimetinib	(rtqknqqhzz) = isodefvlpt lvmlvtnyeq (orodxnfyyv ) View more
NCT03106415 (CTgov)	Phase 1/2	Metastatic breast cancer \| Metastatic Triple-Negative Breast Carcinoma \| Breast Cancer 3	23	pembrolizumab+binimetinib (Phase 1 Dose Level 0)	rkadvklycx(ophjgbetam) = alivezxpbc xlaepkwfrp (qcfohifoxd, htolyoxits - sobivsgqlu) View more	-	20 Aug 2024
				pembrolizumab+binimetinib (Phase 1 Dose Level -1)	rkadvklycx(ophjgbetam) = uofridpdln xlaepkwfrp (qcfohifoxd, ldfdsgzvzm - ylgqubjmdw) View more
ESMO_GI2024 Manual	Not Applicable	BRAF V600E mutant Colorectal Cancer	489	Encorafenib+Binimetinib+Cetuximab	(msuxtyupee) = uxijhbfwfj ipdasvfocx (nfuqgrnnmg, 0.14 - 0.64) View more	Positive	27 Jun 2024
NCT03235245 (EBIN, ASCO2024) Manual	Phase 2	BRAF V600K Mutation-Positive Melanoma \| BRAF V600E Mutation-Positive Melanoma \|	135	Nivolumab + Ipilimumab	(cyjulilcbn): HR = 0.87 (90% CI, 0.67 - 1.12), P-Value = 0.36 View more	Negative	02 Jun 2024
				Encorafenib + Binimetinib +ipilimumab +nivolumab
NCT03839342 (BEAVER, ASCO2024) Manual	Phase 2	Advanced Malignant Solid Neoplasm	23	Binimetinibencorafenib	(dhtrfjkumx) = aqbqmvmums zqrjgwjnvv (peuvuzeexn ) View more	Negative	24 May 2024
				Binimetinib + encorafenib (TP53 mts)	(vtwipbagin) = mluwbtjvpo fzlbmpavcv (hgbsglbsye )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis